Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Spy Crt MARKHAM ON L3R 5H6 |
Tel: | N/A |
Website: | https://www.edesabiotech.com |
IR: | See website |
Key People | ||
Michael J. Brooks President | Pardeep Nijhawan Chief Executive Officer, Corporate Secretary, Director | Stephen Lemieux Chief Financial Officer |
Business Overview |
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company's advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions. |
Financial Overview |
For the three months ended 31 December 2023, Edesa Biotech Inc revenues was not reported. Net loss decreased 28% to $1.7M. Lower net loss reflects Reimbursement grant income increase from $0K to $121K (income), Interest income increase of 23% to $61K (income), Foreign exchange loss decrease of 52% to $3K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.89 to -$0.54. |
Employees: | 16 as of Dec 15, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $10.09M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$8.50M as of Dec 31, 2023 |
Net annual income (TTM): | -$7.72M as of Dec 31, 2023 |
Free cash flow (TTM): | -$6.25M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 3,215,968 as of Apr 2, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |